| 英文名称 | CAS号 | 中文名 | 中文别名 | 分子式 | 分子量 | EINECS号 |
|---|---|---|---|---|---|---|
|
Lapatinib ditosylate
|
388082-78-8 |
二甲苯磺酸拉帕替尼
|
二对苯甲磺酸拉帕替尼;N-(3-氯-4-((3-氟苯基)甲氧基)苯基)-6-(5-(((2-(甲磺酰基)乙基)氨基)甲基)-2-呋喃基)-4-喹唑啉胺二对甲苯磺酸盐水合物;GW-572016;GW572016;二甲苯磺酸拉帕替尼;N-(3-氯-4-((3-氟苯基)甲氧基)苯基)-6-(5-(((2-(甲磺酰基)乙基)氨基)甲基)-2-呋喃基)-4-喹唑啉胺二对甲苯磺酸盐;二对甲苯磺酸拉帕替尼;拉帕替尼二甲苯磺酰酸盐;二甲苯磺酸拉帕替尼;二对甲苯磺酸拉帕替尼;N-(3-氯-4-((4-氟苯基)甲氧基)苯基䀀✀Calibri
|
C43H42ClFN4O10S3 |
925.46 | 642-915-3 |
|
4-Amino-3-chlorophenol
|
17609-80-2 |
4-氨基-3-氯苯酚
|
SYNTHESIS标准品023;4-氨基-3-氯苯酚;3-氯-4-氨基苯酚;N-(2-氯-4-羟苯基)-N'-环丙基-脲的中间体;乐伐替尼原料二的中间体一;4-氨基-3-氯苯酚 1KG;仑伐替尼(乐伐替尼)中间体Ⅴ
|
C6H6ClNO |
143.57 | 241-583-3 |
|
(Z)-2-(5-Amino-1,2,4-Thiadiazol-3-yl-2-Ethoxyiminoacetic Acid /ATDE
|
75028-24-9 |
(Z)-2-(5-氨基-1,2,4-噻二唑-3-基)-2-乙氧亚氨基乙酸
|
(Z)-5-氨基-ALPHA-(乙氧亚氨基)-1,2,4-噻二唑-3-乙酸(头孢洛林7位侧链);(Z)-2-(5-氨基-1,4-噻二唑-3-基)-2-乙氧亚氨基乙酸;氨基噻二唑乙肟酸;(Z)-2-(5-氨基-1,4-噻二唑-3-基)-2-乙氧基亚氨基乙酸;(Z)-5-氨基-ALPHA-(乙氧亚氨基)-1,4-噻二唑-3-乙酸;2-乙氧亚胺基-2-(5-氨基-1,4-噻二唑-3-基)乙酸;ATDE;头孢洛林侧链
|
216.21772 | 616-178-3 | |
|
Lenvatinib Impurity 6
|
796848-79-8 |
N-(2-氯-4-羟苯基)-N'-环丙基-脲
|
乐伐替尼中间体;N-(2-氯-4-羟苯基)-N'-环丙基-脲;N-(2-氯-4-羟基苯基)-N'-环丙基-脲;1-(2-氯-4-羟苯基)-3-环丙基脲;乐伐替尼杂质A;N-(2-氯-4-羟基苯)-N'-环丙基-脲;N-(2-氯-4-羟苯基)-N'-环丙基-脲 乐伐替尼中间体;乐伐替尼杂质LFS-A;N-(2-氯-4-羟苯基)-N'-环丙基-脲 乐伐替尼中间体 1KG
|
C10H11ClN2O2 |
226.65954 | |
|
LCZ696
|
936623-90-4 |
LCZ696
|
沙库巴曲缬沙坦;沙库必曲缬沙坦钠(LCZ696);沙库巴曲缬沙坦钠;塞可比曲缬沙坦;LCZ696;沙库必曲缬沙坦钠盐;奥帕曲拉;缬沙坦;奥帕曲拉
|
C48H58N6O8 |
847.00952 | |
|
2-(methylsulfonyl)-2,45,6-tetrahydropyrrolo3,4-c] pyrazole
|
1280210-80-1 |
MK-312中间体3
|
MK-3102中间体3;2-(甲基磺酰基)-2,4,5,6-四氢吡咯并[3,4-C]吡唑 苯磺酸盐;2,6-四氢-2-(甲基磺酰基)吡咯并[3,4-C]吡唑苯磺酸盐;(OMARIGLIPTIN)MK-3102中间体3;奥格列汀中间体OG-2;奥格列汀中间体1;2-(甲磺酰基)-2,4-C]吡唑苯磺酸盐;(OMARIGLIPTIN)MK-3102奥格列汀 中间体
|
C12H15N3O5S2 |
345.39 | 694-970-8 |
|
Sunitinib Malate
|
341031-54-7 |
苹果酸舒尼替尼
|
SU-11248;SU11248;SUTENT; SUNITINIB;苹果酸舒尼替尼(标准品);N-(2-(二乙基氨基)乙基)-5-((Z)-(5-氟-1,2-二氢-2-氧代-3H-吲哚-3-亚基)甲基)-2,4-二甲基-1H-吡咯-3-甲酰胺 (2S)-羟基丁二酸盐;苹果酸舒尼替尼;苏尼替尼苹果酸盐;SU11248; SUTENT;苹果酸舒尼替尼盐;N-(2-(二乙基氨基)乙基)-(5-氟-1,2-二氢-2-氧代-3H-吲哚-3-亚基)甲基-2,4-二甲基-1H-吡咯-3-羧酸酰胺
|
C22H27FN4O2.C4H6O5 |
532.566 | 638-825-9 |
|
linezolid
|
165800-03-3 |
利奈唑胺
|
吗啉噁酮(利奈唑烷);利萘唑胺;利萘唑酮;利奈唑胺-13C-D4;吗啉恶酮(利奈唑胺);利奈唑酮(雷奈佐利,利奈唑胺);雷奈佐利(利奈唑胺,吗啉恶酮);雷奈佐利(利奈唑胺);利奈唑胺(游离);利奈唑胺
|
C16H20FN3O4 |
337.35 | |
|
sofosbuvir
|
1190307-88-0 |
索非布韦
|
索氟布伟;索氟布韦API;索弗布韦;PSI7977,索非布韦1190307-88-0;索非布韦,索氟布韦1190307-88-0;PSI7977,索非布韦;索非布韦;索菲布韦;N-[[P(S),2'R]-2'-脱氧-2'-氟-2'-甲基-P-苯基-5'-尿苷酰基]-L-丙氨酸异丙酯(索菲布韦)
|
C22H29FN3O9P |
529.452524 | 695-717-4 |
|
Lapatinib
|
231277-92-2 |
拉帕替尼
|
N-[3-氯-4-[(3-氟苯基)甲氧基]苯基]-6-[5-[(2-甲磺酰乙基氨基)甲基]-2-呋喃基]喹唑啉-4-胺;拉帕替尼;拉帕替尼碱;二甲苯磺酸拉帕替尼中间体;GW2016 LAPATINIB;二甲苯磺酸拉帕替尼片;CS-1860;GW 572017LAPATINIB拉帕替尼
|
C29H26ClFN4O4S |
581.057543 | 1806241-263-5 |
|
Brivaracetam
|
357336-20-0 |
布瓦西坦
|
(S)-2-((R)-2-氧代-4-丙基吡咯烷-1-基)丁酰胺/布瓦西坦;布瓦西坛;布瓦斯坦
|
C11H20N2O2 |
212.2887 | |
|
1,2-DICHLORO-1,2-DIFLUOROETHYLENE
|
598-88-9 |
1,2-二氯-1,2-二氟乙烯
|
1,2-二氯-1,2-二氟乙烯;1,2-二氟二氯乙烯
|
C2Cl2F2 |
132.92 | 209-956-5 |
|
(S)-3-Aminopiperidine di hydrochloride
|
334618-07-4 |
(S)-3-氨基哌啶双盐酸盐
|
(S)-3-氨基哌啶双盐酸盐(CAS号:334618-07-4);(S)-3-氨基哌啶双盐酸盐;(S)-3-氨基哌啶二盐酸盐;(S)-(+)-3-氨基哌啶二盐酸盐,96%;(S)-(+)-3-氨基哌啶二盐酸盐,98%;S-氨基哌啶盐酸盐;(S)-(+)-3-氨基哌啶二盐酸盐(S)-(+)-3-氨基哌啶;苯甲酸阿格列中间体B
|
C5H14Cl2N2 |
173.08 | |
|
Vonoprazan Fumarate Impurity 3
|
881674-56-2 |
1-[(2S)-2-吡咯烷羰基]-吡咯烷
|
5-(2-氟苯基)吡咯-3-甲醛;沃诺拉赞中间体:1-[(2S)-2-吡咯烷羰基]-吡咯烷;文诺普兰标准品023;VONOPRAZAN-1;富马酸沃诺拉赞杂质3;5-(2-氟苯基)吡咯-3-甲醛;5-(2-氟苯基)-1H-吡咯-3-甲醛;氟那普拉赞中间体;5-(2-氟苯基)-1H-吡咯-3-甲醛 TAK-438中间体
|
C11H8FNO |
189.1857232 | 809-913-6 |
|
3-Furanol,4-aminotetrahydro-,(3R,4S)-rel-(9CI)
|
330975-13-8 |
(3R,4S)-4-氨基四氢呋喃-3-醇
|
(3R,4S)-4-氨基四氢呋喃-3-醇;反式-4-氨基-四氢呋喃-3-醇
|
C4H9NO2 |
103.12 | |
|
Tert-butyl(2R3S)-2-(2,5-difluorophenyl)-5-oxotetrahydro-2H-pyran-3-yl) carbamate
|
951127-25-6 |
MK-312 中间体1
|
N-[(2R,3S)-2-(2,5-二氟苯基)四氢-5-氧代-2H-吡喃-3-基]氨基甲酸叔丁酯;(5S,6R)-5-(BOC-氨基)-6-(2,5-二氟苯基)四氢吡喃-3-酮;N-[(2R,3S)-2-(2,5-二氟苯基)-5-羟基-四氢-2H-吡喃-3-基]氨基甲酸叔丁酯;MK-3102 中间体1;N-[(2R,5-二氟苯基)四氢-5-氧-2H-吡喃-3-基]-氨基甲酸 1,1-二甲基乙基酯;N-[(2R,5-二氟苯基)四氢-5-氧代-2H-吡喃-3-基]氨基甲酸叔丁酯;(OMARIGLIPTIN)MK3102中间体;奥格列汀中间体OG-1;奥格列汀中间体2
|
C16H19F2NO4 |
327.32 | -0 |
|
Vonoprazan Fumarate Impurity 5
|
881677-11-8 |
5-(2-氟苯基)-1-[(吡啶-3-基)磺酰基]-1H-吡咯-3-甲醛
|
沃诺拉赞中间体:5-(2-氟苯基)-1-[(吡啶-3-基)磺酰基]-1H-吡咯-3-甲醛;5-(2-氟苯基)-1-[(吡啶-3-基)磺酰基]-1H-吡咯-3-甲醛;5-(2-氟苯基)-1-(吡啶-3-取代磺酰基)-1H-吡咯-3-甲醛;富马酸沃诺拉赞中间体2;富马酸氟呐普拉赞中间体;5-(2-氟苯基)-1-(吡啶-3-磺酰基)-1H-吡咯-3-甲醛;沃诺拉赞 N-1;VONOPRAZAN-10
|
C16H11FN2O3S |
330.3335432 | 807-719-6 |
|
Entecavir hydrate
|
209216-23-9 |
恩替卡韦一水合物
|
CS-130;2-氨基-9-[(1S,3R,4S)-4-羟基-3-羟甲基-2-亚甲戊基]-1,9-氢-6-H-嘌呤-6-酮水合物;ETV;BARACLUDE;SQ 34676;BMS 200475;SQ34676;BMS200475;SQ-34676;BMS-200475;2-氨基-9-[(1S,9-氢-6-H-嘌呤-6-酮一水合物;9-(4-羟基-3-羟甲基-2-亚甲基环戊-1-基)鸟嘌呤水合物;恩替卡韦一水合物;恩替卡韦一水物;恩替卡韦;9-(4-羟基-3-羟甲基-2-亚甲基环戊-1-基)鸟嘌呤水合物
|
C12H15N5O3.H2O |
295.3 | 606-668-5 |
|
4-[2-[[(6R,7R)-2-Carboxy-7-[[(2Z)-(ethoxyimino)[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]thio]-4-thiazolyl]-1-methylpyridinium acetate hydrate
|
400827-55-6 |
头孢罗膦
|
4-[2-[[(6R,7R)-2-Carboxy-7-[[(2Z)-(ethoxyimino)[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]thio]-4-thiazolyl]-1-methylpyridinium acetate hydrate;4-[2-[[(6R,7R)-2-carboxy-7-[[(2Z)-(ethoxyimino)[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]thio]-4-thiazolyl]-1-methylpyridinium acetate hydra;TAK 599 acetate H2O;ceftaroline fosamil acetate monohydrate
|
C22H22N8O8PS4.C2H3O2.H2O |
763 | |
|
5-bromo-2-chloro-4'-ethoxydiphenylmethane
|
461432-23-5 |
5-溴-2-氯-4'-乙氧基二苯甲烷
|
4-(5-溴-2-氯苄基)苯乙醚(达格列净中间体);4-(5-溴-2-氯苄基)苯乙醚(达格列净中间体2);5-溴-2-氯-4'-乙氧基二苯甲烷461432-23-5 达格列嗪中间体;达格列嗪中间体研发用 5-溴甲烷;5-溴-2-氯-4'-乙氧基二苯甲烷(达格列净中间体);达格列净中间体 5-溴-2-氯-4'-乙氧基二苯甲烷;4-溴-1-氯-2-(4-乙氧基苯基)苯;5-溴-2-氯-4'-乙氧基二苯甲烷
|
C15H14OClBr |
325.62806 | 636-921-5 |
药智官方微信
药智官方微博
